Vebreltinib is an oral small-molecule MET inhibitor, primarily indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring MET genetic abnormalities. This drug blocks tumor growth signals by inhibiting the activity of the MET protein and must be administered as prescribed by a physician. Common adverse reactions include edema and nausea. Contraindicated populations include individuals hypersensitive to any component of the drug and patients with severe hepatic or renal insufficiency.
Indications and Administration
Indications
Advanced or metastatic non-small cell lung cancer with MET exon 14 skipping mutation (confirmation by genetic testing is required).
Solid tumors with other MET genetic abnormalities (e.g., amplification or overexpression) – under clinical trial stage.
Dosage and Administration
The recommended administration is oral once daily, with the dosage adjusted based on the patient's body weight, disease status and tolerability (e.g., 200 mg per dose).
The tablets may be taken on an empty stomach or with food. Swallow the tablet whole; do not crush or chew.
Pharmacological Mechanism
MET receptor targeting: It selectively inhibits the activity of MET tyrosine kinase, thereby blocking downstream signaling pathways (e.g., RAS-MAPK, PI3K-AKT) and suppressing the proliferation and metastasis of tumor cells.
Anti-angiogenic effect: Preliminary research suggests it may exert an inhibitory effect on tumor angiogenesis.
Adverse Reactions and Management
Common Adverse Reactions (incidence ≥10%)
Edema, asthenia, nausea, anorexia, diarrhea, rash.
Severe Adverse Reactions (immediate medical attention required)
Interstitial lung disease (manifested as dyspnea, cough), elevated liver enzymes, cardiac arrhythmias.
Management Recommendations
Mild adverse reactions may be alleviated by dosage adjustment or symptomatic treatment.
For severe adverse reactions, immediate drug discontinuation and initiation of specialized medical intervention are required.
Contraindications and Precautions
Contraindications
Patients with hypersensitivity to Vebreltinib or any of its excipients.
Patients with moderate to severe hepatic insufficiency (Child-Pugh Class B/C) or severe renal insufficiency (eGFR < 30 mL/min).
Special Populations
Vebreltinib is contraindicated in pregnant and lactating women due to potential teratogenic effects and adverse impacts on the fetus/infant.
Women of childbearing age must use effective contraception during treatment.
Drug Interactions
CYP3A4 inhibitors/inducers: Drugs such as clarithromycin and rifampicin may alter the plasma concentrations of Vebreltinib, requiring appropriate dosage adjustment.
Anticoagulants: Concomitant use may increase the risk of bleeding; close monitoring of coagulation function is necessary.
Storage and Shelf Life
Storage Conditions
Store at room temperature (20-25℃), protected from light and moisture.
Shelf Life
24 months unless otherwise stated on the packaging.
Important Note
Vebreltinib is a prescription-only drug. The specific treatment regimen must be formulated by an oncologist based on genetic testing results. During treatment, patients are required to conduct regular follow-up examinations for liver function, complete blood count, and undergo imaging assessments for treatment efficacy. If suspected adverse reactions occur, contact the attending physician promptly.
